Collection, processing, and banking of umbilical cord blood

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The blood in the umbilical cord and placenta after the birth of a child is comparable to bone marrow for use in hematopoietic stem cell transplantation and offered a number of advantages. In the past 20 years, more than 30,000 cord blood transplants have been performed worldwide. Stem cell transplantation for hematological malignancies and genetic disorders however, is an uncommon occurrence. Research performed by several independent laboratories has demonstrated that cord blood also contains a mixture of pluripotent stem cells capable of giving rise to cells derived from the endodermal, mesodermal, and ectodermal lineages. Thus, CB is a readily available stem cell source for use in tissue engineering and regenerative medicine applications, which are hypothesized to be more frequent events than the need for hematopoietic stem cell transplant. This chapter will review the methodologies for collection, processing, and banking these cells for these future clinical uses.

Original languageEnglish (US)
Title of host publicationPerinatal Stem Cells
PublisherSpringer New York
Pages261-267
Number of pages7
ISBN (Print)9781493911189, 1493911171, 9781493911172
DOIs
StatePublished - Apr 1 2014

Fingerprint

Stem cells
Fetal Blood
Blood
Processing
Transplants
Pluripotent Stem Cells
Inborn Genetic Diseases
Regenerative Medicine
Hematopoietic Stem Cell Transplantation
Stem Cell Transplantation
Hematologic Neoplasms
Tissue Engineering
Hematopoietic Stem Cells
Placenta
Transplantation (surgical)
Stem Cells
Bone Marrow
Parturition
Tissue engineering
Bone

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Collection, processing, and banking of umbilical cord blood. / Harris, David T.

Perinatal Stem Cells. Springer New York, 2014. p. 261-267.

Research output: Chapter in Book/Report/Conference proceedingChapter

Harris, David T. / Collection, processing, and banking of umbilical cord blood. Perinatal Stem Cells. Springer New York, 2014. pp. 261-267
@inbook{b7fd4c541003470182d6d4546efe4b1f,
title = "Collection, processing, and banking of umbilical cord blood",
abstract = "The blood in the umbilical cord and placenta after the birth of a child is comparable to bone marrow for use in hematopoietic stem cell transplantation and offered a number of advantages. In the past 20 years, more than 30,000 cord blood transplants have been performed worldwide. Stem cell transplantation for hematological malignancies and genetic disorders however, is an uncommon occurrence. Research performed by several independent laboratories has demonstrated that cord blood also contains a mixture of pluripotent stem cells capable of giving rise to cells derived from the endodermal, mesodermal, and ectodermal lineages. Thus, CB is a readily available stem cell source for use in tissue engineering and regenerative medicine applications, which are hypothesized to be more frequent events than the need for hematopoietic stem cell transplant. This chapter will review the methodologies for collection, processing, and banking these cells for these future clinical uses.",
author = "Harris, {David T.}",
year = "2014",
month = "4",
day = "1",
doi = "10.1007/978-1-4939-1118-9_24",
language = "English (US)",
isbn = "9781493911189",
pages = "261--267",
booktitle = "Perinatal Stem Cells",
publisher = "Springer New York",

}

TY - CHAP

T1 - Collection, processing, and banking of umbilical cord blood

AU - Harris, David T.

PY - 2014/4/1

Y1 - 2014/4/1

N2 - The blood in the umbilical cord and placenta after the birth of a child is comparable to bone marrow for use in hematopoietic stem cell transplantation and offered a number of advantages. In the past 20 years, more than 30,000 cord blood transplants have been performed worldwide. Stem cell transplantation for hematological malignancies and genetic disorders however, is an uncommon occurrence. Research performed by several independent laboratories has demonstrated that cord blood also contains a mixture of pluripotent stem cells capable of giving rise to cells derived from the endodermal, mesodermal, and ectodermal lineages. Thus, CB is a readily available stem cell source for use in tissue engineering and regenerative medicine applications, which are hypothesized to be more frequent events than the need for hematopoietic stem cell transplant. This chapter will review the methodologies for collection, processing, and banking these cells for these future clinical uses.

AB - The blood in the umbilical cord and placenta after the birth of a child is comparable to bone marrow for use in hematopoietic stem cell transplantation and offered a number of advantages. In the past 20 years, more than 30,000 cord blood transplants have been performed worldwide. Stem cell transplantation for hematological malignancies and genetic disorders however, is an uncommon occurrence. Research performed by several independent laboratories has demonstrated that cord blood also contains a mixture of pluripotent stem cells capable of giving rise to cells derived from the endodermal, mesodermal, and ectodermal lineages. Thus, CB is a readily available stem cell source for use in tissue engineering and regenerative medicine applications, which are hypothesized to be more frequent events than the need for hematopoietic stem cell transplant. This chapter will review the methodologies for collection, processing, and banking these cells for these future clinical uses.

UR - http://www.scopus.com/inward/record.url?scp=84929714742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929714742&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-1118-9_24

DO - 10.1007/978-1-4939-1118-9_24

M3 - Chapter

AN - SCOPUS:84929714742

SN - 9781493911189

SN - 1493911171

SN - 9781493911172

SP - 261

EP - 267

BT - Perinatal Stem Cells

PB - Springer New York

ER -